Folgen
Oliver Kayser
Oliver Kayser
Bestätigte E-Mail-Adresse bei tu-dortmund.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Solid lipid nanoparticles for parenteral drug delivery
SA Wissing, O Kayser, RH Müller
Advanced drug delivery reviews 56 (9), 1257-1272, 2004
16692004
Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future
RH Müller, C Jacobs, O Kayser
Advanced drug delivery reviews 47 (1), 3-19, 2001
16072001
Natural products as antiparasitic drugs
O Kayser, AF Kiderlen, SL Croft
Parasitology research 90 (2), S55-S62, 2003
4632003
The impact of nanobiotechnology on the development of new drug delivery systems
O Kayser, A Lemke, N Hernandez-Trejo
Current pharmaceutical biotechnology 6 (1), 3-5, 2005
4362005
Amphotericin b
A Lemke, AF Kiderlen, O Kayser
Applied microbiology and biotechnology 68 (2), 151-162, 2005
3652005
Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use
HJ Woerdenbag, O Kayser
Journal of herbal medicine 4 (2), 51-73, 2014
3092014
Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme
O Kayser, H Kolodziej
Planta medica 63 (06), 508-510, 1997
2961997
Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide
C Jacobs, O Kayser, RH Müller
International Journal of Pharmaceutics 196 (2), 161-164, 2000
2922000
Formulation of amphotericin B as nanosuspension for oral administration
O Kayser, C Olbrich, V Yardley, AF Kiderlen, SL Croft
International journal of pharmaceutics 254 (1), 73-75, 2003
2682003
Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate
C Olbrich, A Gessner, O Kayser, RH Müller
Journal of drug targeting 10 (5), 387-396, 2002
2232002
Nanosuspensions of poorly soluble drugs—reproducibility of small scale production
MJ Grau, O Kayser, RH Müller
International journal of pharmaceutics 196 (2), 155-159, 2000
2142000
Best practice in research–Overcoming common challenges in phytopharmacological research
M Heinrich, G Appendino, T Efferth, R Fürst, AA Izzo, O Kayser, ...
Journal of Ethnopharmacology 246, 112230, 2020
2012020
Rhodomyrtone: a new candidate as natural antibacterial drug from Rhodomyrtus tomentosa
S Limsuwan, EN Trip, TRHM Kouwen, S Piersma, A Hiranrat, ...
Phytomedicine 16 (6-7), 645-651, 2009
2002009
Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)—effect of surfactants, storage time and crystallinity
C Olbrich, O Kayser, RH Müller
International journal of pharmaceutics 237 (1-2), 119-128, 2002
1962002
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis
N Schöler, K Krause, O Kayser, RH Müller, K Borner, H Hahn, ...
Antimicrobial agents and chemotherapy 45 (6), 1771-1779, 2001
1732001
Pharmacological profile of extracts of Pelargonium sidoides and their constituents
H Kolodziej, O Kayser, OA Radtke, AF Kiderlen, E Koch
Phytomedicine 10, 18-24, 2003
1672003
Endophytic fungi harbored in Cannabis sativa L.: diversity and potential as biocontrol agents against host plant-specific phytopathogens
P Kusari, S Kusari, M Spiteller, O Kayser
Fungal diversity 60 (1), 137-151, 2013
1662013
Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry
RP Maskey, E Helmke, O Kayser, HH Fiebig, A Maier, A Busche, ...
The Journal of antibiotics 57 (12), 771-779, 2004
1632004
Immunomodulatory principles of Pelargonium sidoides
O Kayser, H Kolodziej, AF Kiderlen
Phytotherapy Research 15 (2), 122-126, 2001
1592001
Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR
N Happyana, S Agnolet, R Muntendam, A Van Dam, B Schneider, ...
Phytochemistry 87, 51-59, 2013
1572013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20